[GLP-1受体激活剂:对糖尿病病的影响]
Madeleine Wéra1, Nicolas Paquot1
1Service de diabétologie, nutrition et maladies métaboliques, Centre hospitalier universitaire de Liège, 4000 Liège, Belgique.
Revue medicale suisse
|September 2, 2024
概括
类似葡萄糖-1受体激动剂 (GLP-1RA) 在2型糖尿病患者中提供脏保护. 这项FLOW研究证实了塞马格卢提德的存在.
科学领域:
- 腎臟病學 (nephrology) 是一種醫學專業.
- 内分泌学 在内分泌学.
- 心脏病学 心脏病学
背景情况:
- 糖尿病病 (DKD) 管理涉及血糖控制,解决诸如高血压和脂质失调等并发症,并利用特定药物类.
- 葡萄糖类-1受体激动剂 (GLP-1RA) 已被确立用于降低2型糖尿病 (T2DM) 的心血管风险.
- 新出现的数据表明GLP-1RA在T2DM患有DKD的患者中具有潜在的脏保护益处.
研究的目的:
- 评估GLP-1受体激动剂对2型糖尿病和糖尿病病患者的性保护作用.
- 评估塞马格卢提德对高风险T2DM患者的结局的影响.
主要方法:
- 在FLOW研究中,与安慰剂相比,研究了塞马格卢提德的效果.
- 主要结局侧重于脏事件.
主要成果:
- 这项FLOW研究证实了GLP-1RA的性保护作用.
- 在T2DM患有DKD的患者中,塞马格卢提德显示出显著的脏保护.
结论:
- GLP-1 RAs,特别是塞马格卢提德,在患有DKD的T2DM患者中提供了一种有价值的治疗选择,以保持功能.
- 这些发现支持GLP-1RA在心血管风险降低之外的扩大作用,包括在DKD管理中的脏保护.
相关概念视频
Glucagon-like Receptor Agonists
306
Incretins include glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP), which stimulate insulin secretion post-meals. In type 2 diabetes, GIP's efficacy is reduced, making GLP-1 a viable drug target. GIP originates from preproGIP.
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...
306
Dipeptidyl Peptidase 4 Inhibitors
178
Dipeptidyl peptidase 4 (DPP-4) is a serine protease widely distributed in the body. It's involved in the inactivation of GLP-1 and GIP hormones, which are crucial for insulin regulation. DPP-4 inhibitors, such as sitagliptin (Januvia), saxagliptin (Onglyza), linagliptin (Tradjenta), alogliptin (Nesina), and vildagliptin (Galvus), help increase the proportion of active GLP-1, enhancing insulin secretion. These inhibitors work by competitively binding to DPP-4. This binding causes a...
178
Oral Hypoglycemic Agents: Biguanides and Glitazones
183
Biguanides, particularly metformin (Glucophage), are insulin sensitizers that enhance glucose uptake, thereby reducing insulin resistance. Unlike sulfonylureas, metformin doesn't prompt insulin secretion, which helps to curb hypoglycemia risk. Metformin is beneficial in treating conditions like polycystic ovary syndrome due to its insulin-resistance reduction capability. The drug's primary action involves curtailing hepatic gluconeogenesis, a significant contributor to high blood...
183
Oral Hypoglycemic Agents: Glinides
148
Repaglinide (Prandin) and Nateglinide (Starlix), known as glinides, are oral insulin secretagogues that stimulate insulin release from pancreatic β cells by closing the ATP-sensitive potassium channels (KATP channel). Repaglinide controls insulin release from pancreatic β cells by managing potassium efflux. It shares two binding sites with sulfonylureas and also has a unique site, indicating overlapping mechanisms of action. With a rapid onset and a 4-7 hour duration, it effectively...
148
Oral Hypoglycemic Agents: α-Glucosidase Inhibitors
167
α-glucosidase inhibitors, including acarbose (Precose), miglitol (Glyset), and voglibose (Voglib) (primarily available in Asia), are drugs that control blood sugar levels by delaying the digestion of starch and disaccharides. They achieve this by inhibiting α-glucosidase enzymes in the intestine, which slow the absorption of carbohydrates in the intestine, which in turn leads to a prolonged release of the glucoregulatory hormone GLP-1 from intestinal L-cells.
Acarbose and miglitol are...
Acarbose and miglitol are...
167
Hormones Regulating Blood Glucose
3.2K
Insulin is released by beta cells of the pancreas when blood glucose levels are high. It facilitates glucose absorption and utilization in insulin-dependent cells with insulin receptors on their plasma membranes. Insulin promotes glucose uptake by increasing the number of glucose transport proteins in the cell membrane, allowing glucose to enter the cell. As a result, glucose utilization and ATP production are enhanced.
In addition to accelerating glucose uptake and utilization, insulin has...
In addition to accelerating glucose uptake and utilization, insulin has...
3.2K


